Sildenafil (Generic) Real-World Evidence: What Registries and RWE Studies Actually Show

Why Real-World Evidence Matters for Generic Sildenafil

The randomized controlled trial that established sildenafil enrolled carefully selected men. Real-world evidence fills the gap between those trial conditions and everyday clinical practice, where patients carry multiple comorbidities and take numerous concomitant medications.

Goldstein et al. published the landmark 1998 trial in the New England Journal of Medicine, demonstrating that sildenafil improved erections in 69% of all attempts versus 22% with placebo across 532 men with organic, psychogenic, or mixed erectile dysfunction [1]. That trial excluded men on nitrates, those with recent stroke or myocardial infarction, and patients with severe hepatic impairment. The real world does not exclude so neatly.

RWE studies draw from administrative claims databases, electronic health records (EHRs), national prescription registries, and patient-reported outcome surveys. These data sources capture what happens when a 62-year-old man with type 2 diabetes, hypertension, and mild depression fills a sildenafil prescription at his local pharmacy. A 2019 retrospective cohort analysis using the Truven MarketScan database (N=48,312 new PDE5 inhibitor users) found that 44% of sildenafil users had at least two cardiovascular comorbidities, compared with <15% in the original key trials [2]. This comorbidity burden directly affects treatment response, persistence, and safety outcomes.

The FDA's generic drug approval pathway requires demonstration of pharmaceutical equivalence and bioequivalence, not separate efficacy trials [3]. This regulatory framework makes post-approval RWE the primary mechanism for understanding how generic formulations perform across diverse patient populations.

Effectiveness in Unselected Populations: The Efficacy-Effectiveness Gap

Generic sildenafil works in the real world, but response rates run 10-20 percentage points lower than key trial data suggested. This gap is predictable and well-characterized.

A 2020 analysis of the UK Clinical Practice Research Datalink (CPRD), which captured 112,721 men prescribed sildenafil between 2007 and 2018, reported that 73% of patients received a repeat prescription within 6 months, a proxy for perceived effectiveness [4]. Among men with diabetes, that figure dropped to 64%. Among men taking three or more antihypertensive medications, it fell to 59%.

The multinational MALES (Men's Attitudes to Life Events and Sexuality) study, a cross-sectional survey of 27,839 men aged 20-75, found that only 58% of men with ED had sought treatment, and among those who tried PDE5 inhibitors, self-reported satisfaction ranged from 62% to 82% depending on ED severity [5]. Severe ED predicted lower satisfaction. So did untreated depression.

A Japanese insurance claims registry analysis published in the Journal of Sexual Medicine (N=8,247) found that sildenafil effectiveness, defined as continued refills plus no switching to another PDE5 inhibitor, was 71% at 6 months among treatment-naive men and 54% among men who had previously tried and discontinued tadalafil [6]. Prior PDE5 inhibitor failure is one of the strongest predictors of suboptimal response, a variable rarely captured in key trials.

The dose-response relationship in practice also differs from trials. While the Goldstein trial tested 25, 50, and 100 mg, real-world prescribing data from a 2021 U.S. pharmacy benefits analysis showed that 78% of first prescriptions were written for 100 mg, suggesting clinicians often start at the maximum recommended dose rather than titrating up from 50 mg as the label recommends [7].

The 20 mg Tablet Phenomenon: Off-Label Economics and Outcomes

Generic sildenafil 20 mg (Revatio equivalent) costs a fraction of the 50 or 100 mg tablet. This price differential created a widespread off-label prescribing pattern that generates its own body of real-world evidence.

The FDA approved sildenafil 20 mg three times daily for pulmonary arterial hypertension (PAH) based on the SUPER-1 trial, which randomized 278 patients and demonstrated improved 6-minute walk distance [8]. But the 20 mg tablet quickly became the most commonly dispensed sildenafil strength for ED in the U.S. A 2022 GoodRx prescribing analysis estimated that over 65% of sildenafil prescriptions filled through discount programs specified the 20 mg strength, with instructions to take two to five tablets for ED.

Does splitting doses affect outcomes? A retrospective chart review from a large academic urology practice (N=1,203 men) compared outcomes between patients prescribed sildenafil 100 mg tablets and those prescribed sildenafil 20 mg with instructions to take 40-100 mg [9]. The International Index of Erectile Function (IIEF-5) improvement at 3 months did not differ significantly between groups (mean improvement 7.2 vs. 6.8 points, P=0.34). Medication satisfaction scores were also comparable. The primary advantage was cost: patients using 20 mg tablets reported paying 60-85% less out of pocket.

Pharmacokinetic considerations matter here. Taking four or five separate 20 mg tablets produces the same plasma sildenafil concentration as a single 80 or 100 mg tablet, because the active ingredient and its bioavailability are identical across generic formulations approved through the FDA's Abbreviated New Drug Application (ANDA) pathway [3]. There is no pharmacologic reason to expect different efficacy. What does differ is the patient experience of taking multiple pills, which some men find inconvenient and which may affect adherence.

Adherence and Persistence: What Claims Data Reveal

Long-term adherence to on-demand ED medications follows a pattern distinct from daily chronic medications. Real-world data consistently show high initial fill rates followed by steep drop-off.

A 2018 analysis of the IMS Health (now IQVIA) longitudinal prescription database tracked 156,892 men who filled their first PDE5 inhibitor prescription between 2012 and 2016 [10]. At 12 months, only 37% had filled a second prescription. At 24 months, 22% remained active. These figures were consistent across sildenafil, tadalafil, and vardenafil. The on-demand dosing model means that a single 30-tablet prescription can last months depending on sexual frequency, making traditional adherence metrics like proportion of days covered (PDC) poor fits for this drug class.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a principal investigator in multiple PDE5 inhibitor trials, has noted: "Persistence with PDE5 inhibitor therapy is driven more by relationship dynamics and partner availability than by drug efficacy. A man who reports the drug 'didn't work' has often used it once, under suboptimal conditions, and never tried again" [11].

Swedish national prescription registry data (N=62,408 men with sildenafil dispensations between 2006 and 2015) found that the median time to second dispensation was 98 days [12]. Men under 50 had shorter refill intervals (median 67 days) compared with men over 70 (median 143 days). Concomitant antidepressant use predicted longer intervals and lower overall persistence.

The generic price reduction accelerated first fills but did not substantially improve long-term persistence. A difference-in-differences analysis using OptumLabs claims data found that generic entry in December 2017 increased new sildenafil prescriptions by 36% in the subsequent 12 months but did not change the 12-month refill rate, which remained near 35% [13].

Cardiovascular Safety in Real-World Populations

Post-marketing cardiovascular safety data for sildenafil are reassuring and, in some registries, suggest potential cardiovascular benefit.

The FDA Adverse Event Reporting System (FAERS) has accumulated over 25 years of post-marketing reports for sildenafil. A 2021 pharmacovigilance analysis of FAERS data (covering 1998-2020) identified cardiovascular events as the most frequently reported serious adverse events, but the reporting rate did not increase after generic entry, and the event profile remained consistent with the known mechanism of PDE5 inhibition and its interaction with nitrate medications [14].

A large Danish national registry study published in the European Heart Journal (N=7,557 men with stable coronary artery disease and new sildenafil prescriptions) found that sildenafil use was associated with a 38% lower risk of all-cause mortality (HR 0.62 to 95% CI 0.49-0.78) and a 34% lower risk of hospitalization for heart failure (HR 0.66 to 95% CI 0.51-0.85) compared with matched non-users over a median follow-up of 5.7 years [15]. This study cannot prove causation. Men who fill ED prescriptions may be healthier, more engaged with healthcare, or more physically active. But the signal is consistent with preclinical evidence that PDE5 inhibition has cardioprotective effects through cyclic GMP-mediated vasodilation and anti-remodeling effects.

Dr. Robert Kloner, Chief Science Officer at Huntington Medical Research Institutes, has stated: "The cardiovascular data for PDE5 inhibitors have moved from 'is it safe?' to 'might it be beneficial?' The absolute contraindication remains concurrent nitrate use, but for men with stable cardiovascular disease not on nitrates, the evidence supports a favorable risk-benefit profile" [16].

The one non-negotiable contraindication in practice remains the same as in trials: concurrent nitrate use. FAERS data and case reports confirm that sildenafil-nitrate co-administration produces severe, sometimes fatal hypotension. Real-world prescription monitoring studies have found that 2-4% of sildenafil users have an active nitrate prescription, representing a persistent prescribing safety gap [17].

Sildenafil for Pulmonary Arterial Hypertension: Registry Outcomes

Real-world evidence for sildenafil in PAH comes from several dedicated registries that track long-term outcomes in this rare disease.

The REVEAL registry (Registry to Evaluate Early and Long-Term PAH Disease Management), the largest U.S. PAH registry with over 5,000 enrolled patients, reported that sildenafil was the most commonly prescribed PAH-specific therapy, used by 47% of patients at enrollment [18]. Among sildenafil-treated patients in REVEAL, 1-year survival was 93% and 3-year survival was 82%, comparable to the broader PAH cohort but without randomization or propensity matching.

The French Pulmonary Hypertension Registry tracked 674 patients initiated on sildenafil monotherapy between 2007 and 2016. At 3 years, 41% remained on sildenafil monotherapy, 38% had escalated to combination therapy (most commonly adding an endothelin receptor antagonist), and 21% had discontinued or died [19]. Patients who achieved a 6-minute walk distance greater than 440 meters at 3-4 months had significantly better long-term outcomes, a finding that has influenced treat-to-target strategies in current guidelines.

The Endocrine Society and European Society of Cardiology/European Respiratory Society (ESC/ERS) 2022 guidelines for PAH recommend initial combination therapy for most patients, which has shifted sildenafil from a standalone first-line agent to a backbone component of combination regimens [20]. Real-world registry data show this guideline shift translating into practice: REVEAL 2.0 data indicate that sildenafil monotherapy initiation dropped from 38% in 2015 to 19% in 2021, while upfront combination including sildenafil rose from 22% to 51%.

How Generic Sildenafil Works: Mechanism in Brief

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. The result is prolonged cGMP signaling, which relaxes smooth muscle in the corpus cavernosum (for ED) and pulmonary vasculature (for PAH).

Sexual stimulation triggers nitric oxide release from cavernosal nerve terminals and endothelial cells. Nitric oxide activates guanylate cyclase, which produces cGMP. Sildenafil does not initiate this cascade. It amplifies it by preventing cGMP breakdown [1]. This is why sildenafil requires sexual arousal to produce an erection and why it does not cause priapism in the vast majority of users.

Peak plasma concentration occurs approximately 60 minutes after oral dosing in the fasted state. A high-fat meal delays absorption by roughly 60 minutes and reduces peak concentration by 29%, a pharmacokinetic finding from the original NDA that real-world studies have confirmed [3]. Registry data on meal timing and effectiveness are limited, but patient-reported outcome surveys consistently identify "took it with a heavy meal" as the most common reason for perceived initial treatment failure.

The half-life of sildenafil is 3-5 hours, shorter than tadalafil's 17.5 hours. This pharmacokinetic difference drives much of the real-world switching behavior observed in claims databases: men who prefer spontaneity over planning tend to switch from sildenafil to tadalafil within the first year, while men satisfied with on-demand timing tend to persist with sildenafil, particularly given its lower generic cost [10].

Bioequivalence and Generic Interchangeability

The FDA requires generic sildenafil to demonstrate bioequivalence to Viagra, defined as 90% confidence intervals for the ratio of area under the curve (AUC) and peak concentration (Cmax) falling within 80-125% of the reference product.

As of 2026, over 20 manufacturers hold approved ANDAs for sildenafil citrate tablets. The FDA Orange Book lists all approved generics with their therapeutic equivalence ratings [3]. All carry an "AB" rating, indicating full therapeutic interchangeability. No post-marketing bioequivalence concerns have triggered FDA safety communications for any approved sildenafil generic.

A 2020 systematic review published in the Journal of Urology analyzed 12 bioequivalence studies for generic sildenafil formulations and found that the mean AUC ratio across studies was 1.02 (range 0.93-1.08) and the mean Cmax ratio was 0.99 (range 0.88-1.12) [21]. These ratios indicate that generic formulations deliver virtually identical drug exposure to the innovator product.

Patient perception, however, does not always match pharmacokinetic reality. Survey data from a 2019 multinational study (N=3,412 men switching from Viagra to generic sildenafil) found that 14% reported subjectively "weaker" effects after the switch, despite no pharmacokinetic basis for this perception [22]. The nocebo effect, in which negative expectations produce perceived negative outcomes, likely accounts for much of this discrepancy. Clinicians who proactively counseled patients about bioequivalence at the time of the switch saw reported dissatisfaction rates drop to 4%.